Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy.

Shuanghui Yang,Jianguo Wen,Huan Li,Ling Xu,Yanting Liu,Nianxi Zhao,Zihua Zeng,Jianjun Qi,Wenqi Jiang,Wei Han,Youli Zu
DOI: https://doi.org/10.1002/smll.201900903
2019-01-01
Abstract:Natural killer (NK) cells are a key component of the innate immune system as they can attack cancer cells without prior sensitization. However, due to lack of cell-specific receptors, NK cells are not innately able to perform targeted cancer immunotherapy. Aptamers are short single-stranded oligonucleotides that specifically recognize their targets with high affinity in a similar manner to antibodies. To render NK cells with target-specificity, synthetic CD30-specific aptamers are anchored on cell surfaces to produce aptamer-engineered NK cells (ApEn-NK) without genetic alteration or cell damage. Under surface-anchored aptamer guidance, ApEn-NK specifically bind to CD30-expressing lymphoma cells but do not react to off-target cells. The resulting specific cell binding of ApEn-NK triggers higher apoptosis/death rates of lymphoma cells compared to parental NK cells. Additionally, experiments with primary human NK cells demonstrate the potential of ApEn-NK to specifically target and kill lymphoma cells, thus presenting a potential new approach for targeted immunotherapy by NK cells.
What problem does this paper attempt to address?